Bristol-Myers Squibb Co

NYSE:BMYUnited States

Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. The Company’s pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company’s products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.

Contact Information

Headquarters

430 E 29th St Fl 14NEW YORK, NY, United States 10016-8367

Phone

212-546-4000

Fax

302-655-5049

Executives

Chairman of the Board, Chief Executive Officer

Giovanni Caforio

Executive Vice President, Chief Financial Officer, Member of the Leadership Team

David Elkins

Chief Human Resource Officer, Senior Vice President, Member of the Leadership Team

Ann Powell

Executive Vice President, Chief Digital and Technology Officer, Member of the Leadership Team

Greg Meyers

Executive Vice President, Chief Information Officer, Member of the Leadership Team

Paul von Autenried